Search Results - "Jesús Vivancos, Maria"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    Impact of COVID-19 on the Care of Patients with HIV Infection by Rosas Cancio-Suárez, Marta, Alonso, Cecilia, Vivancos, María Jesús, Pérez-Elías, María Jesús, Cárdenas, María José, Vélez-Díaz-Pallarés, Manuel, Corbacho, María Dolores, Martín-Pedraza, Laura, Muriel, Alfonso, Martínez-Sanz, Javier, Moreno, Santiago

    Published in Journal of clinical medicine (07-06-2023)
    “…The COVID-19 pandemic and associated lockdown measures have been associated with substantial disruptions to health care services, including screening for human…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties by Sanchez Conde, Matilde, Vivancos Gallego, María Jesús, Moreno Guillen, Santiago

    “…Despite the global stabilization of the number of new HIV infections in recent years, there has been an increase in new infections among men who have sex with…”
    Get more information
    Journal Article
  13. 13
  14. 14

    Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting by Casado, Jose L, Monsalvo, Marta, Fontecha, María, Vizcarra, Pilar, Rodriguez, Miguel A, Vivancos, María Jesús, Moreno, Santiago

    Published in HIV research & clinical practice (26-04-2019)
    “…There are scarce data on the combination of dolutegravir (DTG) plus rilpivirine (RPV) in the real world, including patients with hepatitis C virus (HCV)…”
    Get full text
    Journal Article
  15. 15

    Management of Comorbidities in Treated HIV Infection: A Long Way to Go: HIV, comorbidities and aging by Martínez-Sanz, Javier, Serrano-Villar, Sergio, Vivancos, María Jesús, Rubio, Rafael, Moreno, Santiago

    “…Modern ART has now achieved the goal of maintaining HIV RNA suppression with minimum drug-related toxicities. Indeed, in high-income settings, the main health…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells by López-Huertas, María Rosa, Jiménez-Tormo, Laura, Madrid-Elena, Nadia, Gutiérrez, Carolina, Vivancos, María Jesús, Luna, Laura, Moreno, Santiago

    Published in Biochemical pharmacology (01-12-2020)
    “…[Display omitted] Human immunodeficiency virus (HIV) remains incurable due to latent reservoirs established in non-activated CD4 T cells. Current efforts to…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20